Amylyx Pharmaceuticals, Inc. AMLX Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Research And Development Expense Excluding Acquired In Process Cost by Product | ||||||
| AMX0035PSP | $13.35M-22.7% | $17.26M-8.9% | $18.95M-9.3% | $20.89M+20.8% | $17.29M+2.2% | |
| Avexitide | $28.66M+18.9% | $24.1M+20.0% | $20.08M+31.2% | $15.3M+86.7% | $8.19M+196% | |
| Other Programs | $19.68M+27.2% | $15.47M+35.9% | $11.39M-3.7% | $11.82M+17.3% | $10.08M+13.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Amylyx Pharmaceuticals, Inc. break its business down?
- Amylyx Pharmaceuticals, Inc. (AMLX) reports research and development expense excluding acquired in process cost by product across 3 parts — AMX0035PSP, Avexitide and Other Programs. Each is extracted from the segment footnotes and tracked over time.
- Where does Amylyx Pharmaceuticals, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Amylyx Pharmaceuticals, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.